Psychedelic Bulletin
Your weekly update on the psychedelics space. Connect the dots in this fast-paced ecosystem with exclusive insights, analysis, and expert comment.
Psychedelic Bulletin #131: Study Turns Understanding of Psychedelic-Induced Neuroplasticity Inside Out; EU Regulators Show Interest in Psychedelics; What Next for At-Home Ketamine Therapy?
This week, we look at how the European Medicines Agency might be warming up to the idea of psychedelic therapies, how MDMA could be approved in the UK shortly after any FDA approval via a new pathway; and what’s next for at-home ketamine therapy. Plus lots more…
Psychedelic Bulletin #130: Australia to Reschedule MDMA and Psilocybin; Small Pharma Reports Positive DMT Data; Journey Clinical Closes $8.5m Series A
A look at Australia’s rescheduling of MDMA and Psilocybin; Small Pharma’s Phase 2a DMT results; Journey Clinical’s Series A round; and lots more…
Psychedelic Bulletin #129: New Year, New Psychedelic Bills; WHO Dubs 5-MeO-DMT ‘Mebufotenin’
This week: we briefly look at four new psychedelic policy reform bills from across the U.S.; the World Health Organisation gives 5-MeO-DMT a generic name; and more…
Psychedelic Bulletin #128: atai Results Disappoint; MAPS Confirmatory Phase 3 Study “Successful”; New York Bill Would Legalize Psychedelics; Oregon Begins Accepting Licence Applications
This week: PCN-101 results disappoint; MDMA for PTSD appears to have succeeded in second Phase 3 study; a Bill introduced in New York would legalize a number of psychedelics; Oregon begins accepting applications for psilocybin-related licences; and much more…
Psychedelic Bulletin #127: Psilocybin Shows Promise in Bipolar Disorder; Gilgamesh Raises $39m; California Decrim. Bill Returns; Canadian Province Covers Cost of PAT
This week: California’s psychedelics decrim. bill is back on the agenda; COMP360 psilocybin therapy shows promise in bipolar disorder; Gilgamesh closes $39m Series B; and much more…
Psychedelic Bulletin #126: Journey’s Mescaline Patent Pledge; Therapeutic Alliance Doesn’t Predict Response to Psilocybin Therapy, Says COMPASS
This week: Journey Colab’s patent pledge marks an industry first; therapeutic alliance not predictive of psilocybin therapy outcomes, according to COMPASS; psychedelic CPT codes to be considered next February; and much more…